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Abstract 
This paper provides a background to the opioid epidemic in the United States. The opioid 
epidemic, a public health crisis, is perceived by the public to be caused by issues in the medical 
field. By providing a historical background to the epidemic, this study demonstrates that the 
beginnings of the opioid crisis were not only rooted in past issues within the healthcare field but 
in previous social misconceptions about opioids. This historical backdrop is proceeded by an 
examination of opioid pharmacology, which discusses what opioids are, what is currently known 
about opioid addiction and reviews the presently used treatments for opioid use disorder. In 
2010, the federal government sought to mitigate the opioid epidemic through the Patient 
Protection and Affordable Care Act, which included guidelines to reduce prescription opioid 
addiction and offered treatments for opioid use disorder. The Medicaid expansion, which was 
built into this law, sparked controversy; controversy about it having a potentially detrimental 
effect on the opioid epidemic. This study discusses the Medicaid expansion after a summary of 
the Patient Protection and Affordable Care Act to address this controversy. A review of the 
literature on this relationship between the Medicaid expansion and the epidemic suggests that the 
expansion both alleviated and aggravated the opioid crisis. The Medicaid expansion alleviated 
the crisis through increasing the access to opioid abuse treatment, but it also widened the doors 
to prescription opioid abuse. 
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A Background of the Opioid Epidemic and Its Relationship to the Medicaid Expansion 
Introduction 
 The opioid epidemic, by 2017, was well on its way to causing more U.S. citizen deaths 
than World War II. Between 1999 and 2017, approximately 400,000 people overdosed from 
prescription and illicit opioids (Centers for Disease Control and Prevention [CDC], 2018). Now, 
in 2019, the significance of this nationwide crisis remains; as of January, a minimum of 130 
people overdose on opioids per day in the United States (National Institute on Drug Abuse 
[NIH], 2019). 
The opioid epidemic is a multifaceted problem; its roots and its progression are entangled 
with medical and social issues that spanned years. Another layer of complexity is added when 
the impact of legislative actions is considered. An example of a federal action which affected the 
opioid epidemic is the enactment of the Patient Protection and Affordable Care Act (PPACA), 
specifically the Medicaid expansion, which occurred under the presidency of President Barack 
Obama. 
When and how did the opioid epidemic develop? What are opioids and why are they 
addictive? What is being done to doing to combat the opioid epidemic? Is the opioid epidemic 
connected to the Medicaid expansion? These are questions university students and the general 
population ask but struggle to answer because they do not have a grasp of the background of the 
opioid epidemic and the PPACA.  
It is crucial for the people of the United States, especially the next generation of working 
adults, to understand the fundamentals of the opioid epidemic and the relevant legislation to 
answer these questions. Not only would the basic knowledge lead to answers to such questions, 
but it would also enable people to comprehend the contemporary news in which the pervasive 
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opioid epidemic would appear. This basic knowledge about the opioid epidemic and the 
Medicaid expansion can be acquired through familiarizing oneself with the history and science 
behind opioids, the objectives, and mechanisms of the PPACA, and through reviewing the recent 
research and debates surrounding the expansion of Medicaid and its relationship to the opioid 
epidemic.  
The Opioid Epidemic: A Historical Background 
When Purdue Pharma paid a settlement amount of $600 million for misbranding 
OxyContin in 2007, the public became more aware of the unscrupulous marketing that 
pharmaceutical companies are capable of (Jones et al., 2018). Since then, large pharmaceutical 
companies and its owners have been blamed by the public for instigating and worsening the 
current opioid epidemic in the United States (Bebinger, 2019; Meier, 2007; Ng & Cotter, 2019). 
Also, doctors of pain management have pleaded guilty to prescribing opioid medication 
excessively (United States Department of Justice [Justice], 2018b; Justice, 2019a, Justice, 
2019b). The background of this crisis, however, includes more than the marketing tactics of big 
pharma and the overprescription of opioids by clinicians; it involves underlying cultural trends of 
the twentieth century that nurtured the opioid epidemic to be what it is today.  
The Long History Between Opioids and Mankind 
The first record that exists regarding the use of opium, a “juice” extracted from the 
Papaver somniferum (poppy plant), dates back to 4000 BC (Brownstein, 1993; Pathan & 
Williams, 2012; “Sumer”, 2018). Records show that the Sumerians called the plant hul gil, or 
“plant of joy”. More references to opium in ancient history include the texts of the Odyssey, 
which were written by the famous Homer, who lived around 750 BC. Historians believe opium 
made its way to China around the tenth to the thirteenth century through Arab trade routes. 
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Opium reached Europe by the sixteenth century, evidenced by the reports of addiction and 
tolerance in Turkey, England, and Germany (Brownstein, 1993). 
Opium played an important role in initiating and fueling the trade war between the 
Chinese and the British in the first Opium War (1839-42), and among the Chinese, British, and 
French in the second (1856-60). China witnessed a high rise of opium addiction amongst its 
people and was forced to sign unequal treaties of trade. Unfavorable trading and opium addiction 
in China caused a severe weakening of the labor force and economy and is noted today as one of 
the main reasons the Qing dynasty buckled in the twentieth century (Pletcher, 2018). 
A Backdrop to the Current Opioid Epidemic 
The discoveries of the nineteenth century changed how mankind largely used opium and 
opiates (poppy derivatives). Morphine was extracted for the first time in 1806, and heroin was 
created in 1898 and proclaimed non-addictive. In 1850, the hypodermic needle was invented and 
it revolutionized pain medicine; morphine began to be injected as pain medication and as a 
supplement to anesthesia (Brownstein, 1993). However, even with these novel discoveries and 
the rebirth of opium as opiates, the use of them was avoided by both clinicians and patients 
(Jones et al., 2018). 
Opiates and opioids, despite being available for medicinal use, were widely unused until 
the mid-1900s because of two reasons. (Opiates refer to drugs derived from opium, and opioids 
refer to synthetic drugs that behave in a similar manner to the active compounds isolated from 
the poppy plant. Unless there is a need to distinguish between opioids or opiates, opioids assume 
both categories.) First, these analgesics carried a stigma; opioids were widely associated with 
heroin addicts, who were beginning to emerge on the streets (Jones et al., 2018). The Harrison 
Narcotic Act of 1914, enacted as a response to the escalating heroin addiction, also discouraged 
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physicians from prescribing opioids, and “opiophobia” became pervasive (Hunt & Urch, 2013). 
Second, the culture did not regard pain as something to be treated but as a common and natural 
symptom of aging (Jones et al., 2018). In the 1920s, people went as far as to say those who 
received pain medication (who were mostly cancer patients) were “abusers” or “deluded” (Jones 
et al., 2018).  
Society’s opiophobia would have faded slowly, or not at all if it was not for a change in 
the society’s perception of pain that began because of misinformation. In the early 1980s, two 
brief publications emerged and ultimately turned the tide of society’s perspective on pain 
treatment. These publications claimed opioid addiction rates to be low in patients (as low as 
0.03%; Jones et al., 2018). Although both studies did not back up their propositions with 
evidence, researchers and clinicians, and later the public, succumbed to this belief (Jones et al., 
2018). Pain became known as the “fifth vital sign”, diagnosed according to patients’ reported 
pain on a scale of one to ten (Quinones, 2015). The World Health Organization, the Veteran’s 
Health Administration, the Joint Commission, the newly formed American Pain Society, and 
more, campaigned for the increased use of opioids as a treatment for the epidemic of 
undertreated pain (Jones et al., 2018).  
Following the Joint Commission’s rules about providing proper pain control, clinicians 
tried to compensate for the neglect of patient pain by increasing prescription opioids (Jones et al., 
2018). Hospitals became more invested in opioid therapy (Jones et al., 2018), and pharma rapidly 
escalated their revenue by dispensing more opioid medication. Purdue Pharma saw their profit 
reach $1 billion on the cusp of the twenty-first century, after debuting OxyContin in 1996 
(Meier, 2007). McKesson Corporation, Costco Wholesale, and Cardinal Health, large opioid 
manufacturing and distributing companies, are also likely to have made large profits, as they 
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recently reached government settlements for falsely reporting opioid medication orders large in 
size or high in frequency during the early 2000s (Levin Papantonio, n.d.). Since the case 
settlement for misbranding OxyContin in 2007, three executives of Purdue Pharma admitted to 
misinforming physicians, patients, and regulators about the risk of addiction and abuse entailed 
in opioid use (Meier, 2007). 
Such news about fraudulence and deception in pharmaceutical companies has created the 
idea amongst the general public that those in the healthcare system are solely responsible for the 
opioid crisis (Bump, n.d.; Thompson, 2019). In a survey conducted by Siena College Research 
Institute, New Yorkers were asked to pick the single most responsible entity for the opioid 
epidemic. The top three answer choices were the following: “Doctors over-prescribing opioids”, 
“Allowing patients access to too many pain pills”, and “Pharmaceutical companies promoting 
legal drugs without fully warning about risks” (Bump, n.d.).  
While the general public’s blame on pharmaceutical companies and doctors is well-
evidenced by numerous cases, it is important to note that these companies and healthcare 
providers were not exclusively at fault. By prescribing opioids, clinicians were responding to 
more than the “under-treated pain epidemic” and pharmaceutical giants were taking advantage of 
more than the society’s lack of understanding about pain. Clinicians were influenced by societal 
factors more than ever (Knight et al., 2017). In 2017, Knight and colleagues interviewed 23 
primary care clinicians, located in San Francisco, to hear their thoughts on the practice of 
medicine during the growth of the opioid epidemic. The interviewed clinicians discussed how 
there were studies that were done in the mid-‘90s that demonstrated discrimination against 
people with a background in poverty, unsafe communities, and complex and chronic medical 
conditions in the medical field (Knight et al., 2017). According to the interviewees, the results of 
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such research incentivized clinicians to be more attentive and responsive to the patients’ 
complaints, especially about untreated pain. By validating their pain through opioid treatment, 
physicians hoped to increase medication adherence and serve the impoverished with fairness 
(Knight et al., 2017). Knight et al. (2017) simply described the clinicians’ response as “the need 
to do something” (p. 3). 
Pharmaceutical companies and clinicians have been the main targets for the public when 
it comes to the search for the culprits of the opioid epidemic. In 2018, there were reportedly 
more than 600 lawsuits against opioid manufacturers and distributors (Working Partners, 2018). 
Numerous doctors have also been prosecuted for running “pill mills” (Berry, 2018; Justice, 
2018a). While these allegations and legal proceedings do indicate pharma’s and clinicians’ 
involvement in the opioid epidemic, they fail to explain the societal context in which the opioid 
epidemic developed. To a certain extent, clinicians and pharmaceutical companies were not 
simply responsible; they were responders to cultural movements that advocated for “humane 
treatment” for those in pain and that opposed racial and class bias (Jones et al., 2018; Knight et 
al., 2017). An overview of the opioid history shows that the root of the current crisis extends 
beyond the recent years where opioid abuse has received more public attention; instead, it lies in 
the ever-evolving opioid research and the changes in society’s perception of pain and opioids.  
The Opioid Epidemic: A Scientific Background 
To comprehend the medical use of opioids and the treatments available for people 
struggling with opioid addiction, it is important to understand opioid pharmacology. Basic 
pharmacology discusses the way opioids work, its effects, and its uses. This section will, in 
addition to opioid pharmacology, define some terms important for clarifying the meaning of 
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addiction, introduce basic classifications of opioids, and describe common opioid addiction 
treatments.   
Opioids cause analgesia by binding to opioid receptors on a variety of cells. The three 
known receptors include mu, kappa, and delta receptors. Among the three receptor kinds, mu 
receptors are the main mediators of analgesia (Pathan & Williams, 2012). The binding of opioids 
to their receptors induce protein cascades which lead to hyperpolarization of the cell by 
modulating calcium and potassium ion channels (Al-Hasani & Bruchas, 2011). The net effect is 
the reduction of neurotransmitter release. In the midbrain, mu receptor activation follows this 
general pattern of dampening nociceptive signals from peripheral afferent neurons in the spinal 
cord. Thus, a patient’s perceived pain mitigated (Pathan & Williams, 2012). Opioid receptors are 
dispersed throughout both the central and peripheral nervous system but are more concentrated 
in the former. Example loci with opioid receptors in the peripheral nervous system include the 
gastrointestinal tract, heart, immune system, knee joints, vas deferens, and more (Pathan & 
Williams, 2012). The central nervous system, however, is thought to be the seat of opioid 
addiction.  
Research investigating the neurobiology of addiction has largely focused on the 
dopaminergic mesolimbic pathway, which plays a part in controlling motivational states in 
humans and other animals (Hunt & Urch, 2013). Motivational states, which drive motivated 
behaviors, are triggered by homeostatic needs (i.e. thermoregulation) as well as external 
incentives that are aversive or rewarding (Koob, Everitt & Robbins, 2012). The mesolimbic 
pathway, which connects the ventral tegmental area (VTA), the nucleus accumbens, amygdala, 
and the medial prefrontal cortex, is also known as the “reward” pathway (Hunt & Urch, 2013; 
Koob et al., 2012). The primary neurotransmitter of this reward pathway is dopamine (Koob et 
THE OPIOID EPIDEMIC AND MEDICAID   
 
12
al., 2012). Studies have demonstrated links between behaviors associated with drug addiction 
and the activation of the reward pathway (Hunt & Urch, 2013).  
Effects  
Opioid receptor activation causes the feeling of contentedness, satisfaction, and euphoria 
(Pergolizzi, LeQuang, Berger, & Raffa, 2017). Additionally, opioids have multiple side effects 
on the brain and the body. Opioids are neurotoxic and can cause dizziness and sedation (Baldini, 
Von Korff, & Lin, 2012). Relating to the gastrointestinal system, chronic opioid therapy 
commonly causes constipation. In the respiratory system, it causes respiratory system depression 
as well as bradycardia, hypotension, and sleep-disordered breathing, all of which could be life-
threatening. These respiratory effects appear to worsen with higher dosages (Baldini et al., 
2012).  
Dose-dependent side effects also occur in the endocrine system. Opioids impact the 
production of hormones directly at the hypothalamic-pituitary-adrenal axis. Opioids inhibit their 
release from the anterior pituitary. In males, this inhibition may lead to androgen deficiency 
(hypogonadism), and in females, osteoporosis, oligomenorrhea, and galactorrhea (Baldini et al., 
2012). Further research is needed on the musculoskeletal system, cardiovascular system, and 
immune system (Baldini et al., 2012).  
Uses  
In clinical settings, opioids are used as analgesics to alleviate cancer pain, pain at the end-
of-life, and acute pain. They have also been used to treat chronic non-malignant pain (CNMP) 
although, recently, research has questioned the efficacy of opioid medication for CNMP 
treatment (Rosenblum, Marsch, Joseph, & Portenoy, 2008). Outside of the clinical setting, 
opioids are used inappropriately in a variety of ways because of their pleasant effects; people 
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may use opioids to alleviate stress, lighten moods, achieve euphoria, and more (Rosenblum et al., 
2008).  
Addiction, Dependence, and Analgesic Tolerance 
Opioid addiction or opioid use disorder (OUD) is defined by the compulsive use of 
opioids and chronic relapse (Hunt & Urch, 2013). Compulsive use is indicated by the constant 
use of opioids by individuals despite the harm it causes to the physical and psychological health 
of the individual. Relapse in OUD may occur even after many years (Hunt & Urch, 2013). The 
term dependence is not interchangeable with the term addiction (Hunt & Urch, 2013). 
Dependence refers to the physical and psychological effects of withdrawal that occur with a 
sudden drop in dose or stop in drug administration (Hunt & Urch, 2013; Rosenblum et al., 2008). 
Addiction, on the other hand, is a chronic disease where the individual suffers symptoms such as 
craving, along with the loss of control (Hunt & Urch, 2013).  
Analgesic tolerance is also commonly mistaken as a manifestation of opioid addiction. 
Analgesic tolerance is the “decreased subjective and objective effect of the same amount of 
opioids used over time, which concomitantly requires an increasing amount of the drug to 
achieve the same effect” (Rosenblum et al., 2008, p. 7). Thus far, although analgesic tolerance is 
existent in definition, has been debated whether it actually occurs in patients undergoing chronic 
opioid treatment. The current understanding of the scientific community maintains a distinction 
between analgesic tolerance and OUD (Hunt & Urch, 2013).  
Classification of Opioids  
A brief introduction to opioid medication terminology and classification is helpful for 
comprehending the basic pharmacology of OUD medications. The first classification method for 
opioids depends on which receptor(s) the opioid binds to. Even if the opioid binds to more than 
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one, this organization is useful because it infers the potency and side effects of the drug that is 
tied to characteristics of mu, kappa, and delta receptors. This mode of classification is most often 
used in research. Prior to the discovery of synthetic drugs, however, the primary mode of 
classification depended on the chemical composition of the drugs. The categorization depended 
on which opium-extracted compound it was if it was an opiate (Pathan & Williams, 2012). 
In clinical settings and among the general public, opioids are usually classified by their 
effects on opioid receptors. The categories include full agonists, antagonists, partial agonists, and 
mixed agonist/antagonists. Full agonists, such as morphine, produce the maximal effects of 
analgesia through MOR, its preferred opioid receptor. Antagonists have the opposite effect; 
binding produces no functional response and therefore inhibits receptor activation (Pathan & 
Williams, 2012). For example, naloxone is a well-known antagonist drug administered to 
overdosed patients (“Naloxone Injection”, 2016). Partial agonists elicit a limited agonistic 
response, independent of the dose. Mixed agonist/antagonists have both agonistic and 
antagonistic effects, differing according to which receptor they bind to. Both partial agonists and 
mixed agonist/antagonists compete with agonists if agonists are present (Pathan & Williams, 
2012).  
Drug scheduling is a layout used by the United States Drug Enforcement Administration 
(DEA) to grade drugs according to the entailed risk of addiction. Drug scheduling, therefore, is 
not a method of classification based on the innate characteristics of opioids. Drug schedules span 
from Schedule I to Schedule V. Schedule I drugs, such as heroin, are not used in medical settings 
and are labeled for their high potential for addiction (DEA, n.d.). Schedule IV and V drugs, on 
the other end of the spectrum, include drugs that have a low risk for abuse and consist of low 
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amounts of opioids. Although drug scheduling is primarily used by the DEA, it is also used to 
describe different treatment drugs for opioid use disorder (OUD; DEA, n.d.). 
Medical Treatments for Opioid Addiction 
With the establishment of the Fifth Edition of Diagnostic and Statistical Manual of 
Mental Disorders (DSM-5), moderate to severe addiction is referred to as OUD (Substance 
Abuse and Mental Health Services Administration [SAMHSA], 2018). To be diagnosed with 
OUD by current standards, a patient must have had at least two out of eleven of the symptoms 
indicative of OUD within the last year (SAMHSA, 2018). Those with OUD have an option to 
undergo pharmacotherapy accompanied by counseling and behavioral therapy. It is 
recommended the three are done in combination. Altogether, they are called medication-assisted 
therapy (MAT; MedlinePlus, 2018).  
 Those who have OUD receive treatment for various lengths of time, and often individuals 
receive treatment for the rest of their lives. Pharmacotherapy is used in both short-term and long-
term therapies to treat opioid cravings, withdrawal, abuse, addiction, overdose, and more 
(SAMHSA, 2018). Medications approved by the FDA to be used in opioid treatment programs 
(OTP) include methadone, buprenorphine, and naltrexone. These medications have been proven 
repeatedly to play a crucial role in reducing the risk of overdose-induced deaths, the use of illicit 
drugs, and in maintaining positive behavior and habits related to opioid use in those with OUD 
(SAMHSA, 2018). 
Buprenorphine.  As a partial agonist, buprenorphine has a “ceiling” to its negative side 
effects. Its high affinity for mu receptors enables it to compete with other opioids and therefore 
reduces euphoria or side effects the patient is experiencing caused by the other opioids. In those 
who do not have other opioids in their system, it reduces opioid cravings and symptoms of 
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withdrawal (SAMHSA, 2018). Buprenorphine commonly comes in the form of tablets or films 
but can also be injected. Because buprenorphine is susceptible to abuse, it is classified as a 
Schedule III drug and can only be prescribed by physicians, nurse practitioners, and physician 
assistants. It is often combined with naloxone (i.e. Suboxone) to combat misuse. Naloxone is a 
mu receptor antagonist with a short half-life. By combining buprenorphine with naloxone, the 
initial agonistic effects (euphoria) of buprenorphine are masked, and this lowers the likelihood 
for abuse (SAMHSA, 2018). 
Methadone.  Methadone as OUD treatment can be administered as a liquid concentrate, 
powder, tablets, or dispersible tablets. It is the longest known treatment for OUD and research 
shows its use throughout the years has lowered mortality rates and use of illicit drugs 
(SAMHSA, 2018). According to a Cochrane meta-analysis, methadone has a higher rate of 
retaining patients in opioid treatment than buprenorphine and reduces illicit opioid use to the 
same degree as buprenorphine (SAMHSA, 2018). It falls in the category of Schedule II because 
it is a full mu receptor agonist which includes all the effects opioids entail with no ceiling effect, 
unlike buprenorphine (DEA, n.d.). As a Schedule II medication, only OTPs, overseen by 
SAMHSA, may prescribe methadone. According to SAMHSA’s Treatment Improved Protocol 
63 (TIP-63), it is recommended to begin methadone treatment with low doses and increase in 
dose slowly (SAMHSA, 2018). 
The reason to begin “low and slow” is because methadone has less likelihood to lead to 
tolerance if it is administered carefully (SAMHSA, 2018). Specifically, if a certain dose in an 
individual can suppress opioid withdrawal and cravings, this same dose of methadone can be 
used for the rest of the duration of the individual’s treatment. Although methadone use does 
cause various side effects, methadone’s ability to suppress cravings and withdrawal without 
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eliciting euphoria and methadone tolerance makes methadone a commonly used OUD treatment 
(Bart, 2012).  
Naltrexone and naloxone.  Naltrexone is a slow-acting mu receptor antagonist and it 
does not have any effects related to opioids. It merely binds to mu receptors without inducing 
any effects and therefore it will not incur any symptoms of withdrawal when treatment is 
stopped. Naltrexone has a 95% rate of occupying mu receptors and thus displaces other present 
opioid agonists and partial-agonists (Bart, 2012). Therefore, when a person is administered 
naltrexone and other opioids, naltrexone will block the binding of present opioids to the mu 
receptors (SAMHSA, 2018). 
 This medication is most often found in combination with buprenorphine or as a 
prevention mechanism for relapse after medically supervised withdrawal. Although it is useful in 
that it has no abuse liability, treatment adherence is low (SAMHSA, 2018). A likely cause of low 
adherence among those with OUD is naltrexone’s effect of causing precipitated withdrawal 
(Bart, 2012). Precipitated withdrawal occurs when naltrexone is administered prior to the 
clearing of other opioids in a person. If opioids are not clear before treatment with naltrexone, 
withdrawal symptoms may be brought about by the replacement of the bound agonists by 
naltrexone at mu receptors (SAMHSA, 2018). 
Naloxone, like naltrexone, is an opioid receptor antagonist. Unlike naltrexone, naloxone 
is not well-suited as a MAT medication because it works rapidly. Rather, it is used as an 
injection or nasal spray to reverse the effects of an opioid overdose. Many states permit the 
dispensation of naloxone without a prescription, as it is non-addictive and can save lives (Office 
of the Surgeon General, 2018).  
The Affordable Care Act 
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 The Patient Protection and Affordable Care Act (PPACA), colloquially known as 
“Obamacare,” was passed on March 23, 2010, by President Obama (Henry J. Kaiser Family 
Foundation [KFF], 2013).  Short after its legislation, the Health Care and Education 
Reconciliation Act of 2010 was also passed (HealthCare.gov, n.d.a). The PPACA and the Health 
Care and Education Reconciliation Act of 2010 are collectively known as the Affordable Care 
Act or the ACA.  
The ACA’s objectives can be divided into the three following components: to expand 
healthcare, to enhance healthcare, and to slow down the growing cost of healthcare (Davis, 
Guterman, & Bandeali, 2015; KFF, 2013). Through certain commissions and regulations, the 
ACA aimed to expand health insurance coverage and enhance the benefits of the insurance 
(KFF, 2013). There are several components of the ACA that are most relevant for those who are 
interested in educating themselves about the opioid epidemic.  
ACA’s Objectives and Strategies for Implementation 
 The first objective of the ACA, the expansion of health insurance coverage, can 
otherwise be described as decreasing the number of people without healthcare insurance. The 
ACA used several different tactics to accomplish this, including the creation of an individual 
mandate, some employer requirements, the expansion of Medicaid, and the establishment of 
health insurance markets (KFF, 2013). The ACA’s strategies for its second objective, to enhance 
health insurance, can be summarized in three highlights; the well-known essential benefits 
package, a minimum criterion for basic health insurance, and reconstruction of Medicare and 
Medicaid (KFF, 2013).  
 Through examining the ACA, it is important to keep in mind the make-up of the 
uninsured population the ACA planned to minimize. The uninsured, approximately 46.5 million 
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people in 2010, mostly consisted of those who could not financially afford health insurance 
(KFF, 2018). However, there was a portion of uninsured who could afford health insurance but 
opted to not be in any plan. There were also those who were uninsured in previous years because 
of their pre-existing medical conditions, whether they could or could not afford health insurance. 
One reformation which the ACA brought to healthcare focused on this last group. The ACA 
prohibited insurers from refusing insurance plan buyers with pre-existing medical conditions 
(Chernew & Newhouse, 2017).  
The individual mandate and employer requirements.  The individual mandate called 
for every citizen and legal resident in the United States to acquire a health insurance plan. As put 
into effect in 2014, the ACA imposed a tax penalty on those who did not follow the individual 
mandate. The ACA also initiated taxation on larger businesses (50 or more employees) if they 
did not offer health coverage to their employees (KFF, 2013). Smaller businesses, otherwise tax-
exempt, were given tax credit if they did enroll their employees in health insurance plans. Both 
the individual mandate and employer requirements were a part of the ACA’s plan to increase 
access to health coverage and a crucial part of funding the nationwide health insurance coverage.  
Expansion of Medicaid and premium subsidization.  Medicaid, a federal program 
dedicated to subsidizing medical costs for those with limited income, was expanded to include 
more people under the ACA. Prior to the ACA, Medicaid eligibility cut-off determinations were 
complex and strict (KFF, 2015). Eligibility depended on the applicant’s age, whether the 
applicant had dependents and their status in the range of the federal poverty line (FPL). For 
example, in 2013, before the Medicaid income eligibility was changed by the ACA, the average 
income cut-off for working parents was 61% FPL (KFF, 2015). 
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The ACA expanded eligibility up to 138% FPL (KFF, 2015). The ACA also allowed 
those within 100% and 400% FPL to receive premium tax credits. Premium tax credits permitted 
individuals who fell within this range to have a discount for their health insurance premiums 
(HeatlhCare.gov, n.d.b). Under the ACA, the eligibility for CHIP (Children’s Health Insurance 
Program) was also established at 138% FPL for children up to the age of 19. Children within 
133% FPL were also shifted into Medicaid in order to secure health insurance coverage for them 
because, at the time, the future of CHIP continuation remained uncertain (KFF, 2014). 
Health insurance exchanges.  As per the individual mandate, those above 138% FPL 
were likewise required to find health insurance. Those who were in this category could find 
health insurance plans on health insurance exchanges or through their employers if their 
employers offered any. Exchanges titled SHOP (Small Business Health Options Program) were 
also available for any small business wanting to offer health insurance plans to their employees 
(KFF, 2013).  
These online Marketplaces, available beginning 2014, were run by the state or by the 
federal government, depending on the state (Centers for Medicare & Medicaid Services 
[CMS.gov], 2018). However, whether the Marketplace was managed by the state or by the 
federal government, the insurance plans on display were required to meet a national standard for 
quality (further explained under Essential Benefits Package). Exchanges open to individuals and 
SHOP were another part of the ACA’s effort to increase access to health insurance (KFF, 2013).  
Essential benefits package.  Whether it was a plan offered outside of the Exchanges or 
inside, all insurers were required by the ACA to, at a minimum, include the set of medical 
services the essential benefits package listed (KFF, 2013). Each health insurance plan, according 
to the essential benefits package, covered the following: Ambulatory patient services, emergency 
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services, hospitalization, prescription drugs, rehabilitative and habilitative services and devices, 
laboratory services, preventive and wellness services, pediatric services, pregnancy care, 
maternity care, newborn care, and mental health and substance use disorder services 
(HealthCare.gov, n.d.c).   
Medicare and Medicaid reconstruction.  Another method the ACA used to enhance the 
quality of health insurance was by creating and funding the Center for Medicare and Medicaid 
Innovation (CMMI). The CMMI’s purpose was to architect new models of payment for 
Medicare and Medicaid patients and new models of disbursement for healthcare providers (KFF, 
2013).  
One chief scheme of payment put into play with the ACA was between hospitals and the 
national health programs. This new model of payment was contingent on a new rebate system. 
The new rebate system, called bundled-payment, was different in that, instead of the amount of 
reimbursement the health services received depending on the volume of services, it depended on 
the value of the care provided (Abrams et al., 2015).  
States which remodeled their legislative process of medical malpractice also received 
funding. Preventative health care and wellness were encouraged through small changes such as 
requiring franchise food services to display the nutritional content of food (KFF, 2013). 
Prevention and wellness were also promoted through bigger changes, such as investing 11 billion 
to building community health centers, including school-based health centers and nurse-managed 
clinics (KFF, 2013).   
ACA’s objectives and strategies: conclusion.  Overall, the ACA expanded health 
insurance by making it mandatory for all and increasing access to all. To accomplish the latter, 
the ACA helped those who struggled to gain access to health insurance. To help those who could 
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not financially afford insurance meet this law, the ACA extended Medicare and Medicaid 
coverage to more people (KFF, 2013). For those who could not find insurance due to previous 
health conditions, the ACA prevented insurers from refusing such people. For others, who could 
afford insurance but did not have it, the ACA opened up market exchanges of insurance plans 
and required employers to offer health insurance plans (KFF, 2013).  
The expansion of access to healthcare was accompanied by the enhancement of 
healthcare. Enhancing healthcare consisted of both large scale changes, such as establishing new 
models of payment, and small scale changes. The expansion and enhancement made health 
insurance more accessible, affordable, and improved the quality of care (Abrams et al., 2015). 
However, these improvements came with costs. 
ACA’s Mechanisms for Funding 
 
 The ACA enacted by President Obama had multiple arrangements for its financing 
(Chernew & Newhouse, 2017). Taxation and the “pooling” of populations with varying degrees 
of “risk”, two of many financing mechanisms, were not only designed to be sources of funding 
but as means to increase the insured population. Others, such as higher premiums for lower risk 
people and charging for medical services at the point of service, were created to alleviate the 
federal government’s monetary burden by spreading the healthcare costs amongst lower risk 
people (Chernew & Newhouse, 2017).  
Taxation.  The individual mandate penalized those who did not obtain health coverage 
under the ACA. The penalty tax was slowly introduced between 2014 and 2016, when the cost of 
the tax incurred was adjusted to 2.5% of the income reported per family or $695 per adult (KFF, 
2013; Healthcare.gov, n.d.d). The employer requirements, similarly, imposed fines for employers 
who were responsible for full-time employees with tax credits (KFF, 2013). The ACA 
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additionally included a high-cost plan tax (HCPT), colloquially known as the “Cadillac tax.” 
This excision tax planned to tax insurers who offered healthcare plans with expensive premiums 
($10,200 for individuals, $27,500 for families) at a rate of 40% of the plans (Glied & Striar, 
2016)). As of 2018, the enactment of HCPT was pushed back to 2022 (Myers & Jones, 2018).  
Cross-subsidization and others. By requiring all citizens and U.S. residents to receive 
insurance coverage, the ACA did more than increasing the number of people covered by health 
insurance. Through the individual mandate, the employer requirements, and by lowering of 
healthcare plan costs, the ACA sought to pool the healthy, “low-risk” population, with the sick, 
high-risk population (Chernew & Newhouse, 2017). Through pooling, the insurance companies’ 
increased spending was offset by added insurance purchases by people with lower risk (Chernew 
& Newhouse, 2017).  
ACA’s mechanisms for funding: Conclusion. Previously, efforts to make healthcare 
services value-based and payments more efficient were introduced as methods to expand and 
enhance healthcare. However, they were also implemented as mechanisms to slow down the 
growing cost of healthcare. Likewise, efforts to minimize waste and fraud were also methods of 
conserving costs (KFF, 2013). According to Dr. Michael E. Chernew, this topic – pertaining to 
the mechanisms of healthcare funding – is where the main debate lies about the ACA and its 
uncertain future (Chernew & Newhouse, 2017).  
Medicaid Expansion and the Opioid Epidemic 
One of the leading arguments against the ACA associates the Medicaid expansion with 
the opioid epidemic (Adolphsen, 2017). This debate of whether the opioid epidemic was 
worsened by the expansion of Medicaid became especially heated during 2016 and 2017 when 
President Donald Trump was elected and took office. This argument is difficult to address 
THE OPIOID EPIDEMIC AND MEDICAID   
 
24
because the opioid epidemic is a multi-faceted issue and the influence of the Medicaid expansion 
is difficult to quantify; there is no clear cut answer to this debate. There are several arguments for 
and against Medicaid expansion’s role in the opioid epidemic. These arguments are based on a 
wide range of topics, which include the fraud and abuse found in healthcare systems, MAT, 
MAT’s inclusion in the essential benefits package, and more.   
A Comparison of Mortality Rates in Expansion States versus Non-expansion States 
One well-known argument that denies Medicaid expansion as a cause of the epidemic 
focuses on the date of Medicaid expansion (Goodman-Bacon & Sandoe, 2017; Johnson, 2018). 
This argument is a refutation of a study which contrasted drug-related death rates between 
expansion and non-expansion states. The data demonstrated a higher rate of death in expansion 
states between 2010 and 2015 than in non-expansion states (Goodman-Bacon & Sandoe, 2017). 
Those who are advocates of Medicaid expansion point to the date when Medicaid expansion 
began offering essential benefits packages to refute the connection. According to Goodman-
Bacon and Sandoe (2017), the rise in opioid deaths preceded the enactment of the ACA; the 
number of deaths related to opioids doubled during 1999 and 2013, prior to the states’ expansion 
of Medicaid which occurred in 2014. Because the mortality rate was rapidly increasing prior to 
the expansion in 2014, they believe any studies focused on the escalation of death rates between 
2010 and 2014 are irrelevant (Goodman-Bacon & Sandoe, 2017; Thurston, 2017). 
Others, however, do not consider 2014 to be the year in which the Medicaid expansion 
began to exert its effects. Although the implementation of the expansion began in 2014, the law 
was passed in 2010. Those who associate the Medicaid expansion with the epidemic claim that 
states and healthcare providers, therefore, most likely anticipated the coming Medicaid 
expansion and acted accordingly. For the states wishing to expand, this meant encouraging the 
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uninsured to receive coverage, whether it was through their employers, in the market exchanges, 
or through Medicaid. Such anticipatory trends are reflected in the uninsured rates between 2007 
and 2015; expansion states, even prior to 2014 when the individual mandate was launched, had a 
drop in the number of those who were uninsured (Spotted Toad [Toad], 2017). This parallel 
between decreased uninsured rates and the increased death rates suggests the actual expansion 
date of Medicaid as an unreliable setpoint to study regarding the expansion’s connection to the 
opioid epidemic.  
A Comparison of Change in Insurance Coverage Pre-ACA and Post-ACA 
 Another argument which refutes a relationship between Medicaid expansion and the 
opioid crisis is contingent on the magnitude of change in insurance coverage before and after the 
ACA was put into play (Toad, 2017). That is to say, in the research behind this case, regions 
were not compared for expanding or not expanding Medicaid. Instead, regions of the United 
States were sorted by the magnitude of change they saw in their insured population. The regions 
were contrasted to other regions which may have seen less or more changes in insurance 
coverage under the enactment of the ACA.  
The argument presents a comparison between the drug-related mortality rates among 
various counties which were organized according to the amount of change in their uninsured 
population (Goodman-Bacon & Sandoe, 2017). First, they established that areas which had 
higher amounts of uninsured people prior to the enactment of the ACA would see the most 
change in their insurance coverage post-ACA. Therefore, they hypothesized that, if Medicaid 
expansion did have a negative impact on the opioid epidemic, there would be a direct 
correspondence between the degree of change in the uninsured population and the rate of opioid-
related deaths. Goodman-Bacon and Sandoe did not find this correspondence. Their study 
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indicated counties with less insurance coverage before Medicaid expansion had lower rates of 
drug-related deaths. Instead, the regions which had more insurance coverage prior to the 
expansion (and therefore smaller change in uninsured population) had their mortality rates 
increased after the ACA. Thus, they concluded that the Medicaid expansion did not play a role in 
exacerbating the opioid epidemic (Goodman-Bacon & Sandoe, 2017). 
A rebuttal against this research targets the main assumption of Goodman-Bacon and 
Sandoe’s hypothesis (Toad, 2017). According to Toad, the magnitudes of change in insurance 
coverage did not provide accurate prognoses of Medicaid expansion’s impact. He claimed that 
insurance coverage, however, should and did correspond to opioid-related death rates. The areas 
noted for smaller changes in insurance coverage had smaller magnitudes in insurance expansion 
because they were already most covered. He supported his claim by observing the states with 
high growth in overdose rates after the enactment of the ACA. Several of these states had 85% 
insurance coverage prior to the ACA and were considered regions which witnessed a small 
change in insurance coverage in Goodman-Bacon and Sandoe’s study (Toad, 2017). Toad, 
through his research, went beyond refuting Goodman-Bacon and Sandoe’s research. He 
explained that the connection between states with small increases in coverage and their 
heightened mortality rates actually supported the main assertion made by the proponents of the 
“Obamacare-Opioid connection” (Toad, 2017).  
Medicaid Fraud and Abuse 
In addition to Toad, others who advance the Obamacare-Opioid connection emphasize 
the following argument the most: Medicaid expansion intensified the opioid epidemic by 
creating “perverse incentives” which multiplied fraud and abuse (Eberstadt, 2017; Johnson, 
2018). Senator Ron Johnson (2018), like Toad, advanced his position against Medicaid 
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expansion by presenting proof to support such a statement. In 2017, Johnson found 
documentation of 261 individuals charged for abusing the essential benefits offered through 
Medicaid; 80% of the cases he discovered took place in Medicaid expansion states. Johnson also 
discovered the number of such cases to have increased by 55% during the four years after the 
expansion in comparison to the four years prior to it (Johnson, 2018). Johnson also looked 
further into Medicaid-subsidized opioid-related hospitalization spending. In 2018, he discovered 
that Medicaid-subsidized hospitalizations caused by opioid use reportedly increased by 53% 
from the fourth quarter of 2013 to the fourth quarter of 2015 (Johnson, 2018). Medicaid spending 
for OUD and emergency overdose treatments also rose 75% more in expansion states than in 
non-expansion states. He compared these changes with the rates of overdose deaths between 
2013 and 2015; overdoses in expansion states occurred at double the rate of overdoses in non-
expansion states (Johnson, 2018). Altogether, the data demonstrating increases in Medicaid 
spending and mortality rates in Medicaid-expanded states, in combination with the numerous 
cases of fraud and abuse, convinced Johnson that Medicaid expansion had a role in the 
intensification of the opioid epidemic.  
Essentially, Johnson and Toad’s argument contends that the healthcare system’s 
susceptibility to abuse, which is sufficiently revealed in the cases of money laundering doctors 
and pharmaceutical companies in the history of the opioid epidemic, was aggravated by the 
ACA. Nicholas Eberstadt (2017), likewise, reached the same conclusion in his review titled “Our 
Miserable 21st Century”. He grimly summarized this issue by exclaiming “dependence on 
government” took on a morbid meaning in the twenty-first century (Eberstadt, 2017).  
Medicaid Expanded OUD Treatment  
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Those who are for Medicaid do not deny the existence of fraud and abuse within 
Medicaid and the possibility of its role in worsening the opioid epidemic. In a similar fashion, 
proponents of the Obamacare-Opioid connection do not deny the benefits the expansion of 
Medicaid had on the population struggling with OUD. Those who supported the expansion of 
Medicaid strongly advocate its positive impact on the crisis; most notably, its role in increasing 
the access to MAT (Buck, 2011). 
A big step the ACA took towards improving the opioid epidemic was the inclusion of 
substance abuse and mental health services in the essential benefits package (Buck, 2011). The 
substance abuse and mental health treatments offered under Medicaid and private insurance were 
additionally required to cover costs in parity with the out-of-pocket paid under Medicaid. Other 
supplements to increased MAT access included the creation of health homes, which reflects the 
ACA’s overarching attention to developing a more holistic approach to patient care (Buck, 
2011). Recent studies show an increase in prescriptions of Medicaid-endorsed buprenorphine and 
naloxone for OUD, which is indicative of more OUD patients receiving the proper care needed 
to combat addiction (Saloner, Levin, Chang, Jones, & Alexander, 2018; Venkataramani & 
Chatterjee, 2018). Although it is too soon to see if the MAT is effective in the long run of 
mitigating the opioid epidemic, the people in approval of Medicaid expansion consider the 
increased quantity of MAT supplied under the expansion a good sign. 
Another study found more substantial data indicating the positive effect the ACA has had 
on the epidemic. Opioid mortality among young adults was demonstrated to have decreased 
under the ACA. In fact, in Dr. Gal Wettstein’s research, 1% more insurance coverage 
proportionally reduced opioid deaths by 19.8% for young adults (Wettstein, 2019). Whilst it 
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suggests decreased mortality rates for the narrow age group of 19 to 25, Wettstein’s study is a 
mark of the positive impact of the Medicaid expansion on the opioid epidemic (Wettstein, 2019).  
Medicaid Expansion and the Opioid Epidemic: Conclusion 
A large portion of the debate about the connection between Medicaid expansion and the 
opioid epidemic comes in the form of comparing data from non-expansion and expansion states 
or comparing data from before the Medicaid expansion and after it (Goodman-Bacon & Sandoe, 
2017). The leading assertions of the opposing parties, however, are not contradictory to each 
other; instead, they are emphases on different aspects of the relationship between the Medicaid 
expansion and the opioid epidemic. Those who believe that the expansion of ACA exacerbated 
the opioid epidemic stress the pervasive abuse of Medicaid by drug users, dealers, fraudulent 
healthcare providers, and more (Eberstadt, 2017; Johnson, 2018). To the contrary, people who 
strongly advocate that Medicaid expansion benefited the opioid epidemic point out the ACA’s 
role in improving the access to OUD treatment and overall quality of healthcare.  
Neither party is incorrect in their fundamental assertions; Medicaid expansion has 
fostered better care for people struggling from opioid addiction and simultaneous has increased 
the risk of federal funding fraud and abuse (Goodman-Bacon & Sandoe, 2017). Even prior to this 
current opioid epidemic and the establishment of the ACA, opioids had a record marred with 
fraud and misconception. It comes as no surprise that Johnson (2018) found fraud and abuse 
within the workings of Medicaid in light of opioid history. Yet, the ACA’s requirement of health 
insurance for all and its inclusion of MAT such as buprenorphine, methadone, naltrexone, and 
naloxone opened up access to OUD treatment and reduced opioid overdoses (Saloner et al., 
2018; SAMHSA, 2018; Wettstein, 2018). The topic of whether the expansion worsened the 
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opioid epidemic, then, should be addressed more as a question rather than a debate; a question 
with an answer which weighs the strengths and weakness of Medicaid.  
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